Claire Alapetite

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8374954/publications.pdf Version: 2024-02-01



CLAIDE ALADETITE

#	Article	IF	CITATIONS
1	Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial. Neuro-Oncology, 2017, 19, 1661-1672.	1.2	150
2	Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus. Radiotherapy and Oncology, 2018, 128, 26-36.	0.6	112
3	The EPTN consensus-based atlas for CT- and MR-based contouring in neuro-oncology. Radiotherapy and Oncology, 2018, 128, 37-43.	0.6	80
4	Pattern of relapse and outcome of non-metastatic germinoma patients treated with chemotherapy and limited field radiation: the SFOP experience. Neuro-Oncology, 2010, 12, 1318-25.	1.2	77
5	Nonmetastatic pelvic Ewing sarcoma: Report of the French Society of Pediatric Oncology. , 1999, 33, 444-449.		51
6	Management of vertebral radiotherapy dose in paediatric patients with cancer: consensus recommendations from the SIOPE radiotherapy working group. Lancet Oncology, The, 2019, 20, e155-e166.	10.7	51
7	Update of the EPTN atlas for CT- and MR-based contouring in Neuro-Oncology. Radiotherapy and Oncology, 2021, 160, 259-265.	0.6	32
8	Prognostic and predictive values of diffusion and perfusion MRI in paediatric intracranial ependymomas in a large national study. British Journal of Radiology, 2016, 89, 20160537.	2.2	29
9	Pediatric Localized Intracranial Ependymomas: A Multicenter Analysis of the Société Française de lutte contre les Cancers de l'Enfant (SFCE) from 2000 to 2013. International Journal of Radiation Oncology Biology Physics, 2018, 102, 166-173.	0.8	29
10	Patterns of failure after radiotherapy for pediatric patients with intracranial ependymoma. Radiotherapy and Oncology, 2017, 122, 362-367.	0.6	27
11	Water and Electrolyte Disorders at Long-Term Post-Treatment Follow-Up in Paediatric Patients with Suprasellar Tumours Include Unexpected Persistent Cerebral Salt-Wasting Syndrome. Hormone Research in Paediatrics, 2014, 82, 364-371.	1.8	20
12	Risk Factors of Subsequent Central Nervous System Tumors after Childhood and Adolescent Cancers: Findings from the French Childhood Cancer Survivor Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 133-141.	2.5	19
13	Pediatric Chordomas: Results of a Multicentric Study of 40 Children and Proposal for a Histopathological Prognostic Grading System and New Therapeutic Strategies. Journal of Neuropathology and Experimental Neurology, 2018, 77, 207-215.	1.7	18
14	Relapsing intracranial germ cell tumours warrant retreatment. European Journal of Cancer, 2020, 136, 186-194.	2.8	18
15	A rapid review of evidence and recommendations from the SIOPE radiation oncology working group to help mitigate for reduced paediatric radiotherapy capacity during the COVID-19 pandemic or other crises. Radiotherapy and Oncology, 2020, 148, 216-222.	0.6	18
16	Imaging biomarkers of outcome after radiotherapy for pediatric ependymoma. Radiotherapy and Oncology, 2018, 127, 103-107.	0.6	15
17	The European Particle Therapy Network (EPTN) consensus on the follow-up of adult patients with brain and skull base tumours treated with photon or proton irradiation. Radiotherapy and Oncology, 2022, 168, 241-249.	0.6	11
18	High Prevalence of Early Endocrine Disorders After Childhood Brain Tumors in a Large Cohort. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2156-e2166.	3.6	6

CLAIRE ALAPETITE

#	Article	IF	CITATIONS
19	Gliomas, germ cell tumors, and craniopharyngioma. Pediatric Blood and Cancer, 2021, 68, e28401.	1.5	5
20	Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group. Lancet Oncology, The, 2022, 23, e218-e228.	10.7	4
21	Feasibility of Dose Escalation in Patients With Intracranial Pediatric Ependymoma. Frontiers in Oncology, 2019, 9, 531.	2.8	3
22	Assembling the brain trust: the multidisciplinary imperative in neuro-oncology. Nature Reviews Clinical Oncology, 2019, 16, 521-522.	27.6	3